Company intelligence / Profile preview

Vespyr Brands

United States

Ownership: Private
Development stage: Other

Overview

Equivir is in a placebo-controlled clinical trial for upper respiratory tract infections due to complete Q4 2024; BE-Smart Esophageal Pre-Cancer Diagnostics expected for LDT commercialization in Q3 2025

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeDiagnostics
Industry: Biotech

Partnerships

ProPhase Labs (manufacturing agreements and extended partnerships)

Beyond the preview

Go deeper on Vespyr Brands.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vespyr Brands.

Explore the full profile